Replies to post #7 on Karyopharm Therapeutics Inc (KPTI)

[Dspetry]

NEWTON, Mass., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that Nature Neuroscience published data showing Karyopharm's first-in-class oral Selective Inhibitor of Nuclear Export, or SINE(TM), compounds reduce the progression of multiple sclerosis (MS) in preclinical models.

http://www.fiercebiotechresearch.com/press-releases/nature-neuroscience-publishes-data-demonstrating-potential-therapeutic-bene

[Dspetry]

moving along nicely....

Karyopharm Therapeutics announces the issuance of a U.S. Patent for Selinexor - KPTI - 4-16-15

Co announced the issuance of U.S. Patent No. 8,999,996 entitled "Hydrazide Containing Nuclear Transport Modulators and Uses Thereof." This patent, which will expire in 2032 absent any patent term extensions, covers the composition-of-matter of Karyopharm's lead product candidate, selinexor (KPT-330), a first-in-class, oral SINE compound, as well as certain other compositions and related methods.